Article Talks about Neptune’s Push Into China

Neptune Technologies & Bioressources
TSXV: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

In an article titled Neptune Tapping Into China’s Supplement market, published on www.foodnavigator-asia.com, reporter Kacey Culliney interviews Wael Massrieh, VP of Scientific Affairs of Neptune about the company’s recently announced JV deal with Changhi Kai Chuang Deep Sea Fisheris (SKFC) and Neptune’s roll out in China.

“Commercialisation of the venture is underway, said the VP of scientific affairs at Neptune with the company having started the application process.”

In the article, Mr. Massrieh describes the process of entering the supplements market in China. Also, Adam Ismail, executive director of global omega-3 association GOED (Global Organization for EPA and DHA Omega-3s), gives insight into the overall market for omega-3’s in Asia. “…probably the fastest growing market regionally at a rate of between 40 & 50% a year…it’s pretty exciting.”

To view the full article, please click here

Neptune Makes the Move to the TSX – Canada’s Senior Exchange

Neptune Technologies & Bioressources
TSXV: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

Neptune announced today that on November 28, 2011 its shares will begin trading on the Toronto Stock Exchange. Until now, the company has been listed in Canada on the Toronto Venture Exchange. The company has satisfied the more stringent criteria to be listed on the senior board (click here to view the list of requirements), which will result in more potential investors coming to the table. It is fact that a number of investment funds, brokers and investors will only invest in TSX and other senior exchange listed companies.

To view today’s news release, please click here.

Neptune – Dr. Oz says Krill Omega 3 is Superior to Fish Oil

Neptune Technologies & Bioressources
TSXV: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

Yesterday, Dr. Mehmet Oz, the famed host of The Dr. Oz Show did a segment on the powerful cardiovascular benefits of Krill Oil and compared it to regular fish oil. Dr. Oz is known as a massive proponent of fish oil as a source of Omega 3’s, and in yesterday’s episode he said that krill is “better”.

“Krill oil is the new red hot omega 3.”

In the almost 5 minute spot, Dr. Oz explains that fish don’t actually make omega 3’s, they eat omega 3s – one of the things they eat as a source is krill. Another point he makes using an animation is that fish oil omega 3s are not released and absorbed as well as krill oil.

When it comes to cholesterol, Dr. Oz talks about how krill reduces bad cholesterol better than fish oil and in turn reduces plaque in ones arteries.

He also talks about a study that says that 1,000 mg of krill has the same omega 3 affect as 3,000 mg of fish oil. The study he is referring to is the Deutsch et. al, 2004 study done with Neptune Krill Oil (NKO®). Click here to view the paper. In the study, several doses of NKO® were used ranging from 1-3g vs. placebo and fish oil 3g.

Considering the fish oil market is well over $1billion, this kind of endorsement will certainly help Neptune Technologies and Bioressources as the company was recently granted the US patent covering the composition of omega-3 phospholipids comprising polyunsaturated fatty acids. This is a main ingredient found in “all recognized krill oils”.

The Dr. Oz show is the number one rated talk show on TV, with millions of viewers tuning in every week.

To view the segment on Dr. Oz, please click here.

Smartcool Wins Portugal Over With Energy Savings

Smartcool Systems Inc.

TSX.V: SSC
Basic Shares 60.2 million
Fully Diluted 77.4 million
-----------------------------------------------------------------------



Following the November 17th announcement that Smartcool had sold its ESM product to power retailer Metro Groups stores called Makro Cash & Carry in Poland, Smartcool announced today that it will also be installing its product into all eleven Makro outlets in Portugal.

The successful pilot project in Poland provided a return on investment in twenty months which prompted further planned installations into the eleven Makro stores across Portugal which is planned to take place this year.

"We are happy to be expanding into Portugal thanks to our relationship with the Metro Group," says George Burnes, President & CEO of Smartcool. "The Metro Group has thousands of locations worldwide and has clearly recognized the value of Smartcool's energy efficiency solutions. The Metro Group joins our expanding portfolio of clients in the retail industry."

See today's news here....

Solid Resources’ New 3D Drill Tour Of Rare Metals Property & Awarded Spanish Mining Subsidy For 2012

Solid Resources
TSXV - SRW
OTCQX - SLDRF
Shares Outstanding - 93.9 million
Fully Diluted - 129.7 million
--------------------------------------

Today, Solid Resources posted a new 3D animation, which provides investors with an in-depth overview of its Spanish Rare Metals property. The project hosts Tantalum ($150/lb concentrate), Tin ($10/lb), Lithium (1%=22lb/$2.50/lb), Niobium, Rubidium, and Cesium.

Click below to watch the video.



Also, the company announced that for a second year in a row the Spanish Ministry of Industry, Tourism and Trade has granted Solid the maximum subsidy for work committed in 2012. Last year the company received 20 cents back for every dollar is spent on the ground in Spain.

During 2012, the company intends to substantially increase the resource estimates on the concession with an extensive 6,000 m drill program. Information gained from the 2011 program has given Solid an exploration target of reaching over 50 million tonnes in the coming year, not including the northern zone (Presqueiras). Should the company be successful, this would conservatively produce an economical mine with a lifespan of over thirty years.

To view the full news release, please click here.

The Data Behind Neptune’s Latest U.S. Patent - Does It Point At More Important News In The Wings?

Neptune Technologies & Bioressources
TSXV: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

It should be of interest to Neptune shareholders that there’s a bit more colour to be shared around yesterday’s (November 16) announcement that it had been granted another U.S. patent; this time for the exclusive use of krill extracts in the United States as a method for reducing cholesterol, platelet adhesion and plaque formation.

The news came on the heels of last month’s announcement that, “U.S. patent No. 8,030,348 secured Neptune's intellectual property on a composition of novel omega-3 phospholipids, which are the main bioactive ingredients in all krill oils.”

This latest patent finally came to fruition from an initial application to the U.S. patent office that was made in 2001. It was supplemented in 2003 with data obtained from a 3 month clinical study of 120 people with moderate to high cholesterol.

In our discussion with management, it was clarified that the people in the study were provided a daily dosage of 1.0 to 1.5 grams/day (2 to 3 soft gel caps) of Neptune NKO™.

The study proved an average 33% decrease in LDL, which is the aspect covered by the new U.S. patent grant.

The clinical data graphical information is available by clicking on the graphic.

We are told that approximately 100 of the 120 patients were resistant to statins and failed to attain their target LDL levels after at least six months on low dosages.

This new U.S. patent deals with LDL but importantly is one “division” of Neptune’s original patent application. The company is awaiting word from the U.S. patent office on the HDL and Triglyceride components of the application.

Of note, the company expresses no opinion on the timing or the outcome of an announcement from the U.S. patent office.

However, should Neptune be granted patents based on the clinical study’s positive HDL and Triglyceride results with NKO™ versus fish oil, it would be the “perfect trifecta”, which is to simultaneously influence HDL, LDL and Triglycerides while also offering a natural alternative to people resistant to statins.

The “perfect trifecta” is a phrase coined by Dr. Tina Sampalis who is President of Acasti Pharma, 58% owned by Neptune.

Her presentation at The Howard Group’s annual Opportunity Knocks investor conference can be viewed through this link.

The granting of the two patents is also a major benefit to Acasti Pharma (APO – TSX V), which is 58% owned by Neptune. Acasti Pharma is focused on bringing to market, highly purified forms of NKO® (Krill oil) for cardiovascular/cholesterol applications. Acasti’s, CaPre™ is a pharma grade drug candidate that entered a Phase II Clinical Trial in late Q3/2011. Acasti recently commercialized two products in the over-the-counter and medical food areas.

Still on the topic of patents, today Neptune issued a direct and pointed response to the quick filing of a re-examination request of the latest patent by its main competitor, Norway headquartered Aker Biomarine.

The following sums up the position of Neptune management, “Unfortunately, Aker's press release announcing its re-examination request, as well as other related statements made by Aker to the press, appear designed to mislead the public about the validity of Neptune's patent rights and the re-examination process.

It’s clear the two tough competitors are going to remain at loggerheads for some time. Unfortunately, this causes some level of investor discomfort until there is an absolute final answer as to whether or not the U.S. Patent Office will re-examine the patent grants. The timing on that question being answered is unknown. It also wouldn’t be surprising if Aker follows this tact on patents that Neptune is granted in the future.

To read the news release click here.

Pure Nickel Receives $3.5 M Settlement

Pure Nickel
TSX: NIC)(OTCBB: PNCKF)

Basic Shares: 67.8 million
Fully Diluted: 75.5
-------------------------------------------------------------------

The holiday season arrived a little early for Pure Nickel and its shareholders as the company reached a settlement on its interests in the Milford copper property in Utah.

The long standing litigation was resolved with a new U.S. group with significant financial backing that came into the fray a couple of years ago. It ultimately came to terms with creditors that held millions of dollars in paper on the copper project and mill but had to ensure that Pure Nickel was not left out in the cold as it held interests in much of the project.

Pure Nickel has already received the first million dollars of a total of US$3.5 million. Another million is to arrive in 180 days and the balance at the 12 month mark. It also has a 1% Net Smelter Royalty (NSR) capped at US$8 million.

What should make shareholders happy is the company's financial position. It has just over $3 million in cash and with the other $2.5 million, NIC is covered for its current 2012 plans. While budgets can change subject to opportunities, at this point the company doesn't have to think about going to the equity markets, which have been extremely cruel to the junior mining sector through most of 2011.

To read the news release click here.

Smartcool Technology Attracts Massive Global Retailer

Smartcool Systems Inc.

TSX.V: SSC
Basic Shares 60.2 million
Fully Diluted 77.4 million

-----------------------------------------------------------------------

Everyone is looking for ways to save money on their energy bills and Smartcool's technology was the obvious answer for twenty-One Makro Cash & Carry wholesale outlets in Poland. Smartcool's ESM energy savings module will be installed in the stores after a successful pilot project proved a return on investment in 20 months.

Makro is owned by Metro Asset Management Group which is the fourth largest retailer in the world with 2,100 outlets in 33 countries. Could this offer future growth potential for Smartcool?

The company didn't disclose the value of the contract.

See full news release here...

Carfinco Price Target Upped To $11.50

Carfinco Income Fund

TSX: CFN.UN

Units outstanding: 24.61 million
Units fully diluted: 24.65 million
----------------------------------------------------

Immediately following Carfinco reporting its 10th consecutive quarter of record pre-tax earnings, analyst Fred Westra from Industrial Alliance Securities updated his coverage and target price from $9.50 to $11.50.

Mr. Westra mentioned in his report dated November 10th, "We view CFN as not only a good defensive play in volatile markets given its strong credit quality, favourable demographics and used auto sales trends, but as an attractive growth story despite the economic headwinds."

The units have shown considerable strength over the past week moving from the $6.30 range to $6.80 as of this writing.

The full report can be viewed by clicking here....

Video Presentations From Howard Group Opportunity Knocks III Investor Conference Now Here

On October 24th The Howard Group hosted its 3rd annual Opportunity Knocks investor conference in Calgary where five our our clients presented to an audience of investment advisors and private investors.

The following presentations are now available for viewing:

Acasti Pharma: TSX-V: APO

Carfinco Income Fund: TSX: CFN.UN

Solid Resources: TSX-V: SRW - OTCQX - SLDRF

Ventripoint Diagnostics: TSX-V: VPT

A link to view the video presentations for each company can be seen by clicking here.....

Carfinco - Impressive 52.6% Return On Equity in Record Breaking Quarter

Carfinco Income Fund

TSX: CFN.UN
Units outstanding: 24.61 million
Units fully diluted: 24.65 million
--------------------------------------

Carfinco has done it again with the checkered flag waving and a tenth consecutive record pre-tax earnings quarter, this time earning $6 million in Q3, 2011.

During the third quarter the fund achieved an annualized, after-tax return on unitholder's equity of 52.6% - Spectacular!

In yesterday's late news the fund also mentioned that the large servicing contract that it was awarded earlier this year started October 1st and that the fourth quarter earnings will include all of the fees earned from managing this large portfolio, which will provide extra revenue to the fund for the next 24-36 months.

Highlights of Q3:

• Pre-tax earnings for the quarter were $6.0 million, up 21.5% from the $4.9 million for the third quarter of 2010;
• Earnings per fund unit for the quarter was 18 cents;
• Unitholder’s equity increased 7.4% to $34.0 million during the quarter;
• Loan originations for the quarter were $31.7 million, a 22.7% increase from the $25.8 million for the third quarter of 2010;
• Principal balance of finance receivables was $160.3 million, increasing 5.1% during the quarter and 13.6% for the first nine months of 2011, putting us close to our target of 20% growth for the year;
• 31+ days delinquent accounts for the quarter were 2.7%, similar to the 2.6% for the second quarter of 2011 and a decrease from 3.0% for the third quarter of 2010.

On another note, Carfinco management is sharing its great news during extensive meetings throughout Toronto's financial community over the next couple of days.

See full news release here....

Solid Resources CEO - A Letter to Shareholders

Solid Resources
TSXV - SRW
OTCQX - SLDRF
Shares Outstanding - 93.9 million
Fully Diluted - 129.7 million
--------------------------------------

President and CEO, Greg Pendura has issued this letter on the heals of today's announcement that the company will be raising $1 million in a non-brokered private placement.

Dear shareholders,

Solid Resources has never been in a better position to achieve success than right at this current time. I make this statement based on our accomplishments during 2011 and how this has positively positioned the Company for the future. Contrary to the negative pressure all junior resource companies have been enduring since early 2011, Solid is a much stronger company today compared to the start of this year.

Recent Highlights

• The Spanish Ministry of Industry, Tourism and Trade granted Solid the maximum subsidy of 20% for exploration work carried out on the Alberta-1 (Doade-Presqueiras) rare metal concession in NW Spain during 2011
• For 2012, the Ministry has again granted Solid the maximum subsidy available for exploration, based upon our performance in 2011.
• The 2011 drill program, which consisted of 31 drill holes, totaling 3,364 m, has substantiated over 11 km of continuous mineralised dykes. We are extremely confident this will be expanded in 2012.
• The recently announced NI 43-101 resource estimate confirmed 1.6 million tonnes Measured & Indicated and 8 million tonnes Inferred. This report represents less than 10% of the properties potential mineralised zone.
• The results available confirm the expected average contents of the deposit can be estimated in the order of 150 g/t of Tantalum ($150/lb concentrate; $250/lb oxide) 800 g/t of Tin ($10/lb) and 1% Lithium (%= 22 lb/$2.50/lb) if an appropriate, selective mining operation is carried out.
• No other commodity has a greater magnitude of supply shortfall than Tantalum.
• We believe Solid will be in the unique position to become a non-conflict provider of Tantalum and Tin, developing the first Tantalum mine in Europe.
• Europe has identified both Lithium and Tantalum as “critical metals”
• SGS in the UK, is currently conducting a metallurgical study, with results expected in late 2011.

During 2012, we intend to substantially increase the resource estimates on the concession with an extensive 6,000 m drill program. The current information available has given us an exploration target of over 50 million tonnes, not including the northern zone (Presqueiras). This would conservatively produce an economical mine with a lifespan of over thirty years.

I am very proud of the accomplishments Solid has achieved during 2011. Our exploration program exceeded our expectations on the reported tonnage and more importantly, has allowed us to see the significant potential of our rare metal property. All three of our targeted metals – Tantalum, Tin and Lithium are in great demand. None more than Tantalum, which has soared during the previous year to highs of over US $250/lb.

Our world class team of geologists in Spain was the reason our 2011 exploration campaign was on time and on budget. This has allowed our company to enjoy a positive and trusting relationship with the Spanish mining authorities, who are anxious to see the property put into production. Spain is a politically stable, pro-mining country. It understands the positive impact for the workforce and the economy, which mining will provide. Solid’s proven performance in Spain has been the catalyst for the introduction to additional mineral opportunities in the country. I can assure you, while the Alberta -1 (Doade-Presqueiras) property will remain our flagship, we continue to explore all meaningful options to create shareholder value.

Also, I would like to inform you of our recently announced private placement of $1 million. The proceeds will allow us to further enhance and expedite the potential of Alberta-1.

The non-brokered private placement offering has a subscription price of Cdn $0.10 per unit, with an attached warrant exercisable at $0.15 for a period of 24 months. Click here to view today's news release on the private placement.

I think you will agree that there is tremendous potential in the “Solid story”. Should you wish to participate in the private placement, I would invite you to contact Rick Gliege, COO or Shiela Ginn, in our administration department.

Yours truly,

Greg Pendura, President & CEO
Solid Resources Ltd.
780-800-0726
Email-g.pendura@solidresources.com

Contact:
Rick Gliege: tel – 250 751 3661
Email – rick@solidresources.com

Shiela Ginn: tel – 250 247 8689
Email – shiela@solidresouces.com

Analyst BUY & Price Targets For Acasti Pharma & NeptuneTechnologies

Neptune Technologies & Bioressources
TSXV: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

Toronto based Byron Capital Markets biotech analyst, Doug Loe has issued his BUY & target prices for Acasti & Neptune as contained in a just released mammoth 200 page "Healthcare & Biotechnology Sector Review".

He has one-year target prices of $6 for Neptune (Nov. 2 close - $2.70) and $3.50 for Acasti Pharma (Nov. 2 close - $1.25). The targets are in Canadian dollars.

In relation to Acasti, he has modeled scenarios based on a royalty stream starting in F2017 and applied discount rates to Net Present Value, Price/Earnings multiples and Enterprise Value/EBITDA multiples to produce a target range of $2.06 to $4.42. The average was $3.57. The commentary on Acasti starts on Page 121.

Acasti (58% owned by Neptune) is at the front end of a Phase II clinical trial, which is a stepping stone in its quest to ultimately prove it's highly purified form of krill oil will be the natural answer to cholesterol issues.

Analyst Loe briefly mentioned but did not get into the topic of the bluesky valuation potential of Acasti. Amarin (AMRN), which is in Phase III on a fish oil based solution has a market cap around $1 billion and was as high as $2 billion just several months ago.

Acasti has $9 million in the bank and is expected to spend approximately $5 million through 2012 so it's well cushioned through the Phase II.

Neptune's $6.00 target is based on F2014 (Feb.28 year-end) EPS and EBITDA multiples. He's calling for F2013 revenues of just over $28 million and basic EPS of $0.10 and in F2014 revenues of approximately $40.7 million and basic EPS of $0.21.

Neptune has a little more than $13 million in cash and $3.3 million in debt.

The commentary on Neptune starts on Page 147.

To access the analyst report, click here

Pulmonary Arterial Hypertension Validation Trials Begin

VentriPoint Diagnostics Ltd.
VPT - TSX Venture
Shares issued: - 102.6 million
Fully diluted: - 134.0 million

*****************************

VentriPoint Diagnostics has reached a key milestone with today’s announcement that an initial Pulmonary Arterial Hypertension validation trial has started at The University of Chicago Medical Center.

This is significant for the company as the VMS™ PAH (Pulmonary Arterial Hypertension) Diagnostic tool is focused on a very large market. In the U.S. alone, there are about 200,000 hospitalizations annually from PAH alone.

What Is Pulmonary Hypertension?

Pulmonary hypertension, or PH, is increased pressure in the pulmonary arteries. These arteries carry blood from the heart to lungs to pick up oxygen.

PH causes symptoms such as shortness of breath during routine activity (for example, climbing two flights of stairs), tiredness, chest pain, and a racing heartbeat. As the condition worsens, its symptoms may limit all physical activity.

Overview

To understand PH, it helps to understand how your heart and lungs work. Your heart has two sides, separated by an inner wall called the septum.

Each side of your heart has an upper and lower chamber. The lower right chamber of your heart, the right ventricle, pumps blood to your pulmonary arteries. The blood then travels to your lungs, where it picks up oxygen.

The upper left chamber of your heart, the left atrium, receives the oxygen-rich blood from your lungs. The blood is then pumped into the lower left chamber of your heart, the left ventricle. From the left ventricle, the blood is pumped to the rest of your body through an artery called the aorta.

PH begins with inflammation and changes in the cells that line your pulmonary arteries. Other factors also can affect the pulmonary arteries and cause PH. For example, the condition may develop if:

• The walls of the arteries tighten.
• The walls of the arteries are stiff at birth or become stiff from an overgrowth of cells.
• Blood clots form in the arteries.

These changes make it hard for your heart to push blood through your pulmonary arteries and into your lungs. As a result, the pressure in your arteries rises. Also, because your heart is working harder than normal, your right ventricle becomes strained and weak.

Your heart may become so weak that it can't pump enough blood to your lungs. This causes heart failure. Heart failure is the most common cause of death in people who have PH.

PH is divided into five groups based on its causes. In all groups, the average pressure in the pulmonary arteries is higher than 25 mmHg at rest or 30 mmHg during physical activity. The pressure in normal pulmonary arteries is 8–20 mmHg at rest. (The mmHg is millimeters of mercury—the units used to measure blood pressure.)

Other diseases or conditions, such as heart and lung diseases or blood clots, usually cause PH. Some people inherit the condition (that is, their parents pass the genes for PH on to them). In some cases, the cause isn't known.

According to the Thoracic Society of America better tests are needed to make an early diagnosis. The tests should be convenient for screening and could identify persons at risk or give a measure of how severe the disease is.

What is currently available, however, does not adequately assess either risk or severity. Until now.

What Does This Mean For VentriPoint?

Should the trial produce the desired results, the VMS™ PAH system may be the highly accurate, economic and rapid results diagnostic solution that has been sought by cardiologists.

In the news release Dr. Roberto Lang, former President of the American Society of Echocardiography and Director of the Echo Lab states:

“I expect that an assessment of RV volume and function using the VMS™ will become part of the routine clinical ultrasound evaluation for patients at risk for PAH. A simple way to detect and monitor PAH is gravely needed and this methodology will be extremely useful to quantify interventions (therapeutic and surgical) performed on the right ventricle”

Dr. Adams, VentriPoints CEO, comments about the process and what he expects to happen;

“This is a first clinical validation test which should take about 4-6 weeks. When this validation is over we will start the pivotal clinical trial just like the TOF (Tetralogy of Fallot) trial we have ongoing right now.

We estimate the PAH market to be somewhere between $1-2B annually and we are the only company with a solution.

PAH has been identified to us by most of the large ultrasound companies as an application they would love to be able to do but have been unable to figure how. We are discussing with a number of companies how we could partner to bring to market an integrated system for PAH. It is exciting times at VentriPoint.”

Indeed, this is exciting times for VentriPoint.

See the full press release here: